BRPI0414487A - composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo - Google Patents

composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo

Info

Publication number
BRPI0414487A
BRPI0414487A BRPI0414487-2A BRPI0414487A BRPI0414487A BR PI0414487 A BRPI0414487 A BR PI0414487A BR PI0414487 A BRPI0414487 A BR PI0414487A BR PI0414487 A BRPI0414487 A BR PI0414487A
Authority
BR
Brazil
Prior art keywords
receptors
diseases
carboxylic acid
active ingredient
compositions containing
Prior art date
Application number
BRPI0414487-2A
Other languages
English (en)
Inventor
Atsushi Naganawa
Maki Iwahashi
Atsushi Kinoshita
Atsushi Shimabukuro
Seiji Ogawa
Koji Yano
Kaoru Kobayashi
Yataka Okada
Yoko Kishida
Shouji Kawauchi
Kohki Tsukamouto
Yoko Matsunaga
Fumio Nambu
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI0414487A publication Critical patent/BRPI0414487A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)

Abstract

"COMPOSTOS DE áCIDO CARBOXìLICO E COMPOSIçõES MEDICINAIS CONTENDO OS MESMOS COMO O INGREDIENTE ATIVO". A presente invenção refere-se a compostos representados pela seguinte fórmula geral (I) : (I) em que cada símbolo é como definido no relatório descritivo; sais destes, solvatos destes e pró-drogas destes se ligam a receptores de DP e antagonizam os mesmos. Portanto, eles são úteis na prevenção e/ ou tratamento de doenças alérgicas (nefrite alérgica, conjuntivite alérgica, dermatite atópica, asma brónquica, alergia alimentar etc.), doença sistêmica por mastócito, distúrbio sistêmico por ativação de mastócitos, choque anafilático, contração das vias aéreas, urticária, eczema, doenças com prurido (dermatite atópica, urticária etc.), doenças secundárias (catarata, separação da retina, inflamação, infecção, distúrbio do sono etc.) causadas por comportamentos que se associam a prurido (coceira, pulsação etc.), inflamação, doença pulmonar obstrutiva crónica, lesão por reperfusão isquêmica, distúrbios cerebrovasculares, artrite reumatóide, pleurite, colite ulcerativa e assim por diante. Por cauda da ligação específica a receptores de DP, mas somente fraca ligação a outros receptores de prostaglandinas, os compostos acima permitem a produção de drogas com poucos efeitos colaterais.
BRPI0414487-2A 2003-09-17 2004-09-16 composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo BRPI0414487A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003325198 2003-09-17
JP2004101863 2004-03-31
PCT/JP2004/013983 WO2005028455A1 (ja) 2003-09-17 2004-09-16 カルボン酸化合物およびそれらを有効成分として含有する医薬組成物

Publications (1)

Publication Number Publication Date
BRPI0414487A true BRPI0414487A (pt) 2006-11-14

Family

ID=34380314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414487-2A BRPI0414487A (pt) 2003-09-17 2004-09-16 composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo

Country Status (18)

Country Link
US (2) US7601712B2 (pt)
EP (1) EP1666473B1 (pt)
JP (1) JP4919143B2 (pt)
KR (1) KR20060080197A (pt)
AU (1) AU2004274324B2 (pt)
BR (1) BRPI0414487A (pt)
CA (1) CA2539070C (pt)
DK (1) DK1666473T3 (pt)
ES (1) ES2399393T3 (pt)
IL (1) IL174336A (pt)
MX (1) MXPA06002945A (pt)
NO (1) NO20061207L (pt)
NZ (1) NZ545934A (pt)
PL (1) PL1666473T3 (pt)
PT (1) PT1666473E (pt)
RU (1) RU2375353C2 (pt)
TW (1) TWI341838B (pt)
WO (1) WO2005028455A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534904T3 (es) * 2003-01-22 2015-04-30 Senju Pharmaceutical Co., Ltd. Preparación de absorción percutánea para el tratamiento de enfermedad oftálmica, uso del mismo y método para la migración del remedio oftálmico en el tejido tópico en los ojos
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TWI410410B (zh) * 2007-08-10 2013-10-01 Ono Pharmaceutical Co Phenylacetic acid compounds
DE102008059133A1 (de) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
WO2016001452A1 (en) 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
RU2626829C2 (ru) * 2015-11-02 2017-08-02 Анатолий Тимофеевич Корабельников Средство для лечения полипов в пазухах носа и для предотвращения их повторного нарастания, а также способ его применения
SG11202102566YA (en) * 2018-09-20 2021-04-29 Ono Pharmaceutical Co Dp antagonist
JP7047954B2 (ja) * 2020-03-19 2022-04-05 小野薬品工業株式会社 フェニル酢酸化合物を含有する医薬組成物
WO2021187547A1 (ja) * 2020-03-19 2021-09-23 小野薬品工業株式会社 フェニル酢酸化合物の結晶

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5764655A (en) * 1980-10-04 1982-04-19 Nippon Zoki Pharmaceut Co Ltd Novel benzoylaminophenylcarboxylic acid derivative, its preparation, and drug composition comprising it
EP0218728A1 (en) 1985-04-03 1987-04-22 Yamanouchi Pharmaceutical Co. Ltd. Phenylene derivatives
BR0109050A (pt) 2000-03-09 2004-04-27 Ono Pharmaceutical Co Derivados de indol, processo para prepapação e uso dos mesmos
MXPA04009095A (es) * 2002-03-19 2004-12-06 Ono Pharmaceutical Co Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
AU2003227325B2 (en) * 2002-08-02 2009-05-28 Scientific Games, Llc Lottery ticket security method
EP1591441A4 (en) * 2003-02-07 2007-10-31 Ono Pharmaceutical Co CARBON ACID COMPOUNDS
MXPA05011536A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.

Also Published As

Publication number Publication date
US20070004716A1 (en) 2007-01-04
RU2375353C2 (ru) 2009-12-10
CA2539070A1 (en) 2005-03-31
DK1666473T3 (da) 2013-03-25
AU2004274324A1 (en) 2005-03-31
US8138335B2 (en) 2012-03-20
NZ545934A (en) 2009-05-31
RU2006112573A (ru) 2007-10-27
EP1666473B1 (en) 2013-01-02
ES2399393T3 (es) 2013-04-01
EP1666473A1 (en) 2006-06-07
CA2539070C (en) 2011-12-13
TWI341838B (en) 2011-05-11
IL174336A0 (en) 2006-08-01
TW200524886A (en) 2005-08-01
PT1666473E (pt) 2013-02-15
US7601712B2 (en) 2009-10-13
US20100029631A1 (en) 2010-02-04
MXPA06002945A (es) 2006-06-14
JPWO2005028455A1 (ja) 2006-11-30
NO20061207L (no) 2006-06-19
EP1666473A4 (en) 2009-06-03
WO2005028455A1 (ja) 2005-03-31
JP4919143B2 (ja) 2012-04-18
KR20060080197A (ko) 2006-07-07
AU2004274324B2 (en) 2009-11-05
IL174336A (en) 2012-01-31
PL1666473T3 (pl) 2013-05-31

Similar Documents

Publication Publication Date Title
BRPI0516482A (pt) 2, 6-substituìda-4-monossubstituìda-amino-pirimidina como antagonistas receptor de prostaglandina d2
BR0109050A (pt) Derivados de indol, processo para prepapação e uso dos mesmos
NO20061207L (no) Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel
PH12019501098A1 (en) Pyrrolopyrimidines as cftr potentiators
NO20081370L (no) Fenyl-[1,2,4]-okadiazol-5-on-derivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
TW200639151A (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
UA95950C2 (en) 2,6-substituted-4-monosubstituted amino-pyrimidineasprostaglandin d2 receptor antagonists
NO20043894L (no) Karboksysyreforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
MY145648A (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
BR112014007694B1 (pt) Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
TNSN08515A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
EP2892885A1 (de) Herbizid wirksame bicycloarylcarbonsäureamide
BR112013020536A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2
JP6970691B2 (ja) Ｔｒｐｖ４拮抗薬
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
MX2015006677A (es) Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimeti lcarbamoil-ciclohexilamina para el tratamiento de sintomas negativos de la esquizofrenia.
ES2649018T3 (es) Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
WO2009064836A3 (en) Kynurenine-aminotransferase inhibitors
EA200701898A1 (ru) Производные диаза-спиро-[4.4]-нонана в качестве антагонистов нейрокинина (nk1)
CN107207407A (zh) 用于治疗疾病和病症的组合物和方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]